📊 LMAT Key Takeaways
Is Lemaitre Vascular Inc. (LMAT) a Good Investment?
LeMaitre Vascular demonstrates exceptional operational profitability with 72.7% gross margins and 26.7% operating margins, coupled with a fortress balance sheet featuring zero debt and exceptional liquidity (14.32x current ratio). However, zero revenue growth year-over-year coupled with weak capital returns (3.9% ROE, 2.5% ROA) indicate the company is a mature cash generator rather than a growth business, failing to effectively deploy its $629.5M asset base.
LeMaitre Vascular shows exceptional profitability (71.5% gross, 27.2% operating margin) and a debt-free, highly liquid balance sheet, converting cash efficiently (29.8% FCF margin). Net income and EPS grew ~31% despite flat revenue, indicating mix improvement and operating discipline. The key to sustaining results is reigniting organic growth while preserving margin gains.
Why Buy Lemaitre Vascular Inc. Stock? LMAT Key Strengths
- Exceptional gross margin of 72.7% and operating margin of 26.7% demonstrate strong pricing power and operational efficiency in medical devices
- Zero debt with fortress balance sheet: 14.32x current ratio and 13.27x quick ratio provide financial safety and strategic flexibility
- Sustainable profitability with 23.6% net margin and positive free cash flow generation of $12.3M (18.5% FCF margin)
- Debt-free balance sheet with exceptional liquidity
- High and expanding profitability with strong margins
- Robust free-cash-flow generation and low capex needs
LMAT Stock Risks: Lemaitre Vascular Inc. Investment Risks
- Critical: Zero revenue growth (0.0% YoY) indicates business stagnation with no market expansion in medical devices sector
- Severely weak capital efficiency with only 3.9% ROE and 2.5% ROA despite high profitability suggests excessive asset base or goodwill from acquisitions
- EPS growth of 30.6% driven entirely by non-operational sources (share buybacks, lower share count) masks underlying growth weakness
- Flat revenue growth may cap upside and operating leverage
- Margin gains could normalize amid pricing/reimbursement pressures
- Niche portfolio concentration; growth may rely on new products or M&A execution
Key Metrics to Watch
- Revenue growth acceleration - critical to demonstrate expansion beyond current 0% YoY stagnation
- Return on Equity and Return on Assets improvement - measure whether management can deploy substantial asset base more efficiently
- Operating cash flow and capital allocation decisions - track whether free cash flow sustains or indicates asset write-downs
- Organic revenue growth (YoY)
- Operating margin and FCF margin sustainability
Lemaitre Vascular Inc. (LMAT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.32x current ratio provides a solid financial cushion.
LMAT Profit Margin, ROE & Profitability Analysis
LMAT vs Healthcare Sector: How Lemaitre Vascular Inc. Compares
How Lemaitre Vascular Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lemaitre Vascular Inc. Stock Overvalued? LMAT Valuation Analysis 2026
Based on fundamental analysis, Lemaitre Vascular Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lemaitre Vascular Inc. Balance Sheet: LMAT Debt, Cash & Liquidity
LMAT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lemaitre Vascular Inc.'s revenue has grown significantly by 62% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.34 reflects profitable operations.
LMAT Revenue Growth, EPS Growth & YoY Performance
LMAT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $47.4M | $6.0M | $0.33 |
| Q2 2024 | $50.1M | $6.0M | $0.36 |
| Q1 2024 | $47.1M | $6.0M | $0.27 |
| Q3 2023 | $39.0M | $3.5M | $0.25 |
| Q2 2023 | $42.1M | $3.5M | $0.16 |
| Q1 2023 | $39.6M | $6.0M | $0.27 |
| Q3 2022 | $38.4M | $3.5M | $0.25 |
| Q2 2022 | $40.7M | $3.5M | $0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lemaitre Vascular Inc. Dividends, Buybacks & Capital Allocation
LMAT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lemaitre Vascular Inc. (CIK: 0001158895)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LMAT
What is the AI rating for LMAT?
Lemaitre Vascular Inc. (LMAT) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LMAT's key strengths?
Claude: Exceptional gross margin of 72.7% and operating margin of 26.7% demonstrate strong pricing power and operational efficiency in medical devices. Zero debt with fortress balance sheet: 14.32x current ratio and 13.27x quick ratio provide financial safety and strategic flexibility. ChatGPT: Debt-free balance sheet with exceptional liquidity. High and expanding profitability with strong margins.
What are the risks of investing in LMAT?
Claude: Critical: Zero revenue growth (0.0% YoY) indicates business stagnation with no market expansion in medical devices sector. Severely weak capital efficiency with only 3.9% ROE and 2.5% ROA despite high profitability suggests excessive asset base or goodwill from acquisitions. ChatGPT: Flat revenue growth may cap upside and operating leverage. Margin gains could normalize amid pricing/reimbursement pressures.
What is LMAT's revenue and growth?
Lemaitre Vascular Inc. reported revenue of $66.6M.
Does LMAT pay dividends?
Lemaitre Vascular Inc. pays dividends, with $5.7M distributed to shareholders in the trailing twelve months.
Where can I find LMAT SEC filings?
Official SEC filings for Lemaitre Vascular Inc. (CIK: 0001158895) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LMAT's EPS?
Lemaitre Vascular Inc. has a diluted EPS of $0.68.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LMAT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Lemaitre Vascular Inc. has a BUY rating with 77% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is LMAT stock overvalued or undervalued?
Valuation metrics for LMAT: ROE of 3.9% (sector avg: 15%), net margin of 23.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LMAT stock in 2026?
Our dual AI analysis gives Lemaitre Vascular Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LMAT's free cash flow?
Lemaitre Vascular Inc.'s operating cash flow is $15.1M, with capital expenditures of $2.8M. FCF margin is 18.5%.
How does LMAT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 23.6% (avg: 12%), ROE 3.9% (avg: 15%), current ratio 14.32 (avg: 2).